Guiding Appropriate Cancer Treatment with Molecular Residual Disease Testing : Episode 7

Video

February 9, 2022

INSPIRE and IMvigor011 Trials

Jason Starr, DO, discusses the INSPIRE and IMvigor011 studies that focused on the use of ctDNA in MRD.

EP: 1.Explaining Molecular Residual Disease

EP: 2.The Evolution of Circulating Tumor DNA in Oncology

EP: 3.MRD Assessments

EP: 4.MRD Results and Guiding Treatment Decisions

EP: 5.MRD and Value-Based Care Models

EP: 6.Supporting MRD Availability

Now Viewing

EP: 7.INSPIRE and IMvigor011 Trials

EP: 8.Potential Changes for MRD in the Future

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Ovarian cancer | Image Credit: tashatuvango - stock.adobe.com

June 27th 2025

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

Kristi Rosa

Mirvetuximab soravtansine continues to show efficacy and safety in the final analysis of the phase 2 PICCOLO study.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Myasthenia gravis diagnosis | Image Credit: Maggie L. Shaw/sora.chatgpt.com

June 19th 2025

RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis

Abigail Lewis

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.

Doctor speaking to a female patient with obesity | Image credit: Studio Romantic - stock.adobe.com

June 18th 2025

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Laura Joszt, MA

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.